一家累计亏损18亿元的 生物医药 企业，高管年薪却集体突破200万元，研发投入腰斩的同时，实控人薪酬翻倍。2024年，当百奥赛图在财报中高调宣布“阶段性扭亏为盈”时，董事长沈月雷的薪酬从205万元飙升至425.9万元。同年，这家公司研发投入却锐减53.6%，从2022年的6.99亿元断崖式降至3.24亿元。一边是累计未弥补亏损高达18.4亿元的财务黑洞，一边是高管薪酬逆势暴涨的狂欢。这家顶着“基因...
Source Link一家累计亏损18亿元的 生物医药 企业，高管年薪却集体突破200万元，研发投入腰斩的同时，实控人薪酬翻倍。2024年，当百奥赛图在财报中高调宣布“阶段性扭亏为盈”时，董事长沈月雷的薪酬从205万元飙升至425.9万元。同年，这家公司研发投入却锐减53.6%，从2022年的6.99亿元断崖式降至3.24亿元。一边是累计未弥补亏损高达18.4亿元的财务黑洞，一边是高管薪酬逆势暴涨的狂欢。这家顶着“基因...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.